Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES Journal of Chemotherapy Pub Date : 2024-07-01 Epub Date: 2023-10-20 DOI:10.1080/1120009X.2023.2270833

Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin, Mohammad Ma'koseh

{"title":"Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.","authors":"Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin, Mohammad Ma'koseh","doi":"10.1080/1120009X.2023.2270833","DOIUrl":null,"url":null,"abstract":"This retrospective study aimed to assess the characteristics and predictors of infusion-related reactions (IRRs) to rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). The medical records of adult patients with B-NHL who received their first cycle of rituximab from August 2020 to August 2022 were reviewed. IRRs were defined as any signs experienced by patients during rituximab infusion and graded according to the Common Terminology Criteria for Adverse Events. During the study period, 334 patients were included; among them, 100 patients (30%) developed IRRs (mean age 54.7 (SD 13.2) years). Of the reported IRRs, 90% were grade II reactions, and 10% were grade III reactions. The multivariate analysis identified indolent lymphoma [OR 1.90, p = 0.025], no hydrocortisone as premedication [OR 3.03, p = 0.029], thrombocytopenia [OR 2.55, p = 0.009], and absolute lymphocyte count ≥ 2000 lymphocytes/microL [OR 1.74, p = 0.045] as independent predictors for IRRs.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"291-298"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2023.2270833","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

This retrospective study aimed to assess the characteristics and predictors of infusion-related reactions (IRRs) to rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). The medical records of adult patients with B-NHL who received their first cycle of rituximab from August 2020 to August 2022 were reviewed. IRRs were defined as any signs experienced by patients during rituximab infusion and graded according to the Common Terminology Criteria for Adverse Events. During the study period, 334 patients were included; among them, 100 patients (30%) developed IRRs (mean age 54.7 (SD 13.2) years). Of the reported IRRs, 90% were grade II reactions, and 10% were grade III reactions. The multivariate analysis identified indolent lymphoma [OR 1.90, p = 0.025], no hydrocortisone as premedication [OR 3.03, p = 0.029], thrombocytopenia [OR 2.55, p = 0.009], and absolute lymphocyte count ≥ 2000 lymphocytes/microL [OR 1.74, p = 0.045] as independent predictors for IRRs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

B细胞非霍奇金淋巴瘤患者对利妥昔单抗输注相关反应的特征和预测因素。

这项回顾性研究旨在评估B细胞非霍奇金淋巴瘤（B-NHL）患者对利妥昔单抗的输注相关反应（IRRs）的特征和预测因素。回顾了2020年8月至2022年8月接受第一周期利妥昔单抗治疗的B-NHL成年患者的医疗记录。IRRs被定义为患者在利妥昔单抗输注过程中出现的任何体征，并根据不良事件通用术语标准进行分级。在研究期间，纳入334名患者；其中，100名患者（30%）出现IRRs（平均年龄54.7（SD 13.2）岁）。在报告的IRR中，90%为II级反应，10%为III级反应。多变量分析确定惰性淋巴瘤[OR 1.90，p = 0.025]，术前不使用氢化可的松[OR 3.03，p = 0.029]，血小板减少症[OR 2.55，p = 0.009]，绝对淋巴细胞计数≥2000个淋巴细胞/微升[OR 1.74，p = 0.045]作为IRRs的独立预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.